Open AccessPrognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients
Author(s) -
Athanasios Κotsakis,
Filippos Koinis,
Afroditi Katsarou,
Marianthi Gioulbasani,
Despoina Aggouraki,
Nikolaos Kentepozidis,
Eleni-Kyriaki Vetsika
Publication year - 2016
Publication title -
scientific reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.24
H-Index - 213
ISSN - 2045-2322
DOI - 10.1038/srep39247
Subject(s) - lung cancer , value (mathematics) , cell , medicine , cancer research , oncology , biology , genetics , mathematics , statistics
The role of the different circulating regulatory T-cells (Treg) subsets, as well as their correlation with clinical outcome of non-small cell lung cancer (NSCLC) patients is poorly understood. Peripheral blood from 156 stage III/IV chemotherapy-naive NSCLC patients and 31 healthy donors (HD) was analyzed with flow cytometry for the presence and functionality of CD4 + Treg subsets (naive, effector and terminal effector). Their frequencies were correlated with the clinical outcome. All CD4 + Treg subsets exhibited highly suppressive activity by TGF-β and IL-10 production. The percentages of naive Treg were found elevated in NSCLC patients compared to HD and were associated with poor clinical outcome, whereas the percentage of terminal effector Treg was lower compared to HD and higher levels were correlated with improved clinical response. At baseline, normal levels of naive and effector Treg were associated with longer overall survival (OS) compared to high levels, while the high frequency of the terminal effector Treg was correlated with longer Progression-Free Survival and OS. It is demonstrated, for first time, that particular CD4 + Treg subtypes are elevated in NSCLC patients and their levels are associated to the clinical outcome. The blocking of their migration to the tumor site may be an effective therapeutic strategy.